Open AccessJournal Article
Inhibition of the enkephalin-metabolizing enzymes by the first systemically active mixed inhibitor prodrug RB 101 induces potent analgesic responses in mice and rats.
Florence Noble,J M Soleilhac,Evelyne Soroca-Lucas,Serge Turcaud,M.-C. Fournie-Zaluski,Bernard-Pierre Roques +5 more
Reads0
Chats0
TLDR
The preferential involvement of mu opioid receptors in the analgesic effects of endogenous enkephalins, whose extracellular levels are increased by the two RB101-generated inhibitors, is suggested.Abstract:
N-([(R,S)-2-benzyl-3[(S)(2-amino-4-methylthio)butyl dithio]-1-oxopropyl)-L-phenylalanine benzyl ester (RB101) is the first systemically active prodrug generating through a biologically dependent cleavage of the disulfide bond the potent (S)2-amino-1-mercapto-4-methylthio butane (aminopeptidase N) (IC50 = 11 nM) and N-[(R,S)-2-mercapto-methyl-1-oxo-3-phenylpropyl]-L-phenylalanine (neutral endopeptidase) (IC50 = 2 nM) inhibitors (aminopeptidase N). RB101 easily crosses the blood-brain barrier, as shown by the observed complete inhibition of cerebral endopeptidase 24.11 after i.v. injection in mice. The prodrug induces strong, dose-dependent antinociceptive responses in mice after i.v., i.p. or s.c. administration, in the hot plate (ED50 = 9 mg/kg) and phenylbenzoquinone-induced writhing (ED50-3.25 mg/kg) tests in mice, which are currently used in analgesics screening. RB101 is also active in the tail-flick and tail-electric stimulation tests in rats. In contrast, under disulfide forms, the above selective aminopeptidase N or endopeptidase 24.11 inhibitors are inactive after i.v. administration and their association 3 times less potent than RB101 alone. In all the tests used, the pain-alleviating effect of RB101 was suppressed by naloxone, but, except for the tail-flick and the motor response to tail-electric stimulation, not by the delta-selective antagonist naltrindole. The preferential involvement of mu opioid receptors in the analgesic effects of endogenous enkephalins, whose extracellular levels are increased by the two RB101-generated inhibitors, is suggested by the similar apparent pA2 values for RB101-naloxone (pA2: 7.53 +/- 0.046) and DAMGO (mu-selective ligand)-naloxone (pA2: 7.38 +/- 0.049).(ABSTRACT TRUNCATED AT 250 WORDS)read more
Citations
More filters
Journal ArticleDOI
Aminopeptidase-N/CD13 (EC 3.4.11.2) inhibitors: chemistry, biological evaluations, and therapeutic prospects.
Brigitte Bauvois,Daniel Dauzonne +1 more
TL;DR: An update on the biological and pharmacological profiles of known natural and synthetic APN inhibitors and current status on their potential use as therapeutic agents is discussed with regard to toxicity and specificity.
Journal ArticleDOI
CCK-B receptor: chemistry, molecular biology, biochemistry and pharmacology
Florence Noble,Bernard P. Roques +1 more
TL;DR: The strategies followed to design these probes, and their use to study the anatomy of CCK pathways, the neurochemical and pharmacological properties of this peptide and the clinical perspectives offered by manipulation of the CCK system will be reported.
Journal ArticleDOI
Inhibiting the breakdown of endogenous opioids and cannabinoids to alleviate pain.
TL;DR: The effects of Dual enkephalinase inhibitors and FAAH inhibitors are compared and the progress in their rational design is described, to consider the challenges in their clinical development and opportunities for combination therapies.
Journal ArticleDOI
Δ9-tetrahydrocannabinol releases and facilitates the effects of endogenous enkephalins: reduction in morphine withdrawal syndrome without change in rewarding effect
Olga Valverde,Florence Noble,Françoise Beslot,Valérie Daugé,Marie-Claude Fournie-Zaluski,Bernard P. Roques +5 more
TL;DR: Behavioural and biochemical results demonstrate the existence of a direct link between endogenous opioid and cannabinoid systems, however, chronic use of high doses of cannabinoids does not seem to potentiate the psychic dependence to opioids.
Journal ArticleDOI
Antidepressant-type effects of endogenous enkephalins protected by systemic RB 101 are mediated by opioid delta and dopamine D1 receptor stimulation.
Ana Baamonde,Valérie Daugé,Mariano Ruiz-Gayo,Ion Gigel Fulga,Serge Turcaud,Marie-Claude Fournie-Zaluski,Bernard P. Roques +6 more
TL;DR: The results support the occurrence of tonic and phasic controls of mood-related behaviour by endogenous enkephalins through delta and D1 receptor stimulation and suggest a possible future use of these mixed inhibitors as new antidepressants.